Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Overview of attention for article published in Blood, January 2004

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user

patent: 10 patents
guideline: 4 clinical guideline sources

Readers on

mendeley: 190 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 10 patents that reference this research output.

Dosing for treatment with anti-CD20/anti-CD3 bispecific antibody

Grant US-12729243-B2

United States of America

08 Sep 2026

Means and methods for treating DLBCL

Grant US-10696744-B2

United States of America

30 Jun 2020

MEANS AND METHODS FOR TREATING DLBCL

Application US-20160208001-A1

United States of America

21 Jul 2016

Diffuse Large B-Cell Lymphoma Markers and Uses Therefor

Application US-20150148254-A1

United States of America

28 May 2015

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 6 additional patents.